Litigation Endorsed As Postmarket Safety Tool
U.S. District Judge Jack Weinstein expounded on the value of litigation in promoting drug safety in denying Lilly's motion to dismiss a Zyprexa lawsuit. "Allowing this and like suits to proceed may or may not increase the cost of pharmaceuticals and the efficacy of medical treatment in this country," Weinstein wrote in a June 28 opinion. "It does, however, furnish backstop protection against under-regulated potentially dangerous activity by a market where caveat emptor largely rules."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth